Gut Microbiota and Oral Contraceptive Use in Overweight and Obese Patients with Polycystic Ovary Syndrome

Creative Commons License

EYÜPOĞLU N. D., ERGÜNAY K., AÇIKGÖZ PINAR A., AKYÖN YILMAZ Y., Yilmaz E., Yildiz B. O.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol.105, no.12, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 105 Issue: 12
  • Publication Date: 2020
  • Doi Number: 10.1210/clinem/dgaa600
  • Journal Name: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Food Science & Technology Abstracts, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Keywords: microbiome, dysbiosis, oral contraceptive, PCOS, obesity, BACTERIAL, DYSBIOSIS, RISK
  • Hacettepe University Affiliated: Yes

Abstract

Context: Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder. Emerging animal and human data point to various changes in microbiota that could be linked with the syndrome. However, the effects of therapeutic approaches on gut microbial composition in women with PCOS remain unknown.